About EEP
Investment Orientation
The Team




Investor Reporting
Contact Us
Site Map
Terms & Conditions

EEP News

CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe

7th May 2015

CMC Biologics, Inc., a global leader in clinical and commercial manufacturing, announced today a plan to expand its global manufacturing capacity by more than 30,000 liters in the United States and Europe to meet growing customer demands for late-stage and commercial manufacturing.

“This global expansion addresses increasing demands from our customers for late-stage and commercial manufacturing,” said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. “CMC Biologics is investing in innovative facility design to provide the production flexibility needed to meet aggressive regulatory and production timelines and speed our customers’ products to market.”

Additional information on CMC Biologics’ global facility expansion in Copenhagen, Seattle and Berkeley will be released in the following weeks. Follow our news on LinkedIn at: https://www.linkedin.com/company/cmc-biologics and on our website at www.cmcbiologics.com.

About CMC Biologics
CMC Biologics is leading the industry among CMO’s in reliability, technical excellence, and quality – Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale‐up and cGMP manufacture of protein- based therapeutics for pre‐clinical, clinical trials and commercial production. The Company’s wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics’ proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed‐batch and perfusion production processes. .

More detailed information can be found at www.cmcbiologics.com.

Back to News

EEP Advisers Limited is Authorised and Regulated by the Financial Conduct Authority